Systematic Analysis of Gene Mutations and Therapeutic Efficacy via Ex vivo Hematological VitroScreen Platform

Acute myeloid leukemia (AML) is the most common hematological malignancy, with FLT3 mutations emerging as a key therapeutic target. Other mutations like TP53, TET2, and the overexpression of drug-resistance genes also influence treatment sensitivity. The poster highlights champions' hematological VitroScreen platform offering a cost-effective solution for screening new FLT3 inhibitors and other novel anti-cancer agents for AML. Additionally, the Lumin platform integrates multi-omic data from Champions' tumor models with public datasets, enabling efficient model selection and data interpretation.

• The ex vivo hematological VitroScreen platform offers an efficient and cost-effective method for testing drug performance.

• Our study findings demonstrate that FLT3 mutations enhance the sensitivity to FLT3 inhibitors, while TP53 mutations and S100A8 overexpression decrease sensitivity to standard-of-care treatments, consistent with clinical trial observations.

• The integration of the Lumin bioinformatics platform with the ex vivo hematological VitroScreen platform provides a powerful tool for drug development.